Clinical Trial

RT-310 Dose Escalation BPH Study

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
RT-310, a novel implant, is intended to minimally invasive treat locally the prostate gland for the management of prostate disease, while minimizing side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-11-13; most recent amendment 2025-11-21.
Status change: Recruiting → Active, Not Recruiting 2025-11-21
Status change: Not Yet Recruiting → Recruiting 2023-11-29
Trial Details
NCT Number NCT06136819
Lead Sponsor Resurge Therapeutics Inc.
Conditions BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms
Enrollment 20 participants
Start Date 2024-04-19
Primary Completion 2025-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-28